Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 461
- Locations
- 1
- Primary Endpoint
- Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT)
Study Overview
Brief Summary
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
- •Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment
Exclusion Criteria
- •Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
- •Participation in a clinical trial at baseline and during the follow-up period
Arms & Interventions
Degarelix
Intervention: Degarelix (Drug)
LHRH agonist
Intervention: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat) (Drug)
Outcomes
Primary Outcomes
Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT)
Time Frame: Up to 4 years
Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' comorbidities at the point of decision making and during ADT
Time Frame: Up to 4 years
Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' concomitant medications at the point of decision making and during ADT
Time Frame: Up to 4 years
Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' risk factors at the point of decision making and during ADT
Time Frame: Up to 4 years
Measured by questionnaires by quantifying the frequency of urologists' entries
Secondary Outcomes
No secondary outcomes reported